Mena FN

PD-1 And PD-L1 Inhibitors Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, And Future Outlook

DelveInsight's“ PD-1 and PD-L1 Inhibitors Competitive landscape 2025 ” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape ...
Business Wire

CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts 2023-2034 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
Business Wire

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Phase 1 clinical study to assess effect of cudetaxestat on pharmacokinetics of two approved therapies for idiopathic pulmonary fibrosis (IPF) Company on track to initiate planned phase 2 clinical ...
Mena FN

NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: Competitive Landscape, Emerging Therapies, Leading Companies, And Future Outlook By Delveinsight

"NLRP3 Protein Inhibitors Clinical Trials"NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome ...

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Research Report 2025: Next-Gen TKIs and Immunotherapy Show Promise for EGFR Lung Cancer

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...